



*August 31, 2016*

Federal Communications Commission  
445 12<sup>th</sup> Street SW  
Washington, DC 20554

Subject: Limited Agency Agreement  
Ascensia Diabetes Care US Inc.  
FCC ID: VN5-O5

To Whom It May Concern:

We, Ascensia Diabetes Care US Inc., hereby authorized Intertek Testing Services to act as our Agent for the purpose of preparing application for FCC ID number: VN5-O5 under all applicable parts of the FCC rules and regulations.

The effective date of this limited agency agreement is August 31, 2016. The Limited Agency Agreement expires on August 30, 2018, unless sooner terminated or extended by written notice to Intertek Testing Services and the Federal Communications Commission.

This is to advise that we are in full compliance with the Anti-Drug Abuse Act. The applicant is not subject to a denial of federal benefits pursuant to Section 5301 of the Anti-Drug Act of 1988, 21 U.S.C. 862, and no party to the application is subject to a denial of federal benefits pursuant to that section.

If you have any questions or comments, please do not hesitate to contact me.

Sincerely,

A handwritten signature in black ink that reads "Kevin Chang". The signature is fluid and cursive, with the first letters of the first and last names being capitalized.

Kevin Chang – R&D Quality Engineer

Ascensia Diabetes Care US Inc.  
430 S. Beiger Street  
Mishawaka, Indiana 46544  
U.S.A.

Tel: +1 574 256-3420  
Fax: +1 574 257-3065  
E-mail: [kevin.chang@ascensia.com](mailto:kevin.chang@ascensia.com)